20
Participants
Start Date
December 21, 2022
Primary Completion Date
July 23, 2025
Study Completion Date
July 23, 2025
Iadademstat
Patients will be treated with iadademstat given at a dose of 150 microgram PO administered on a 5 day on-2 day off schedule every week (days 1 through 21)
Paclitaxel
Patients will be treated with Paclitaxel given at a dose of 80 mg/m2 intravenous administration weekly day 1, 8 and 15 (days 1 through 21).
Roswell Park Cancer Institute, Buffalo
Fox Chase Cancer Center, Philadelphia
Huntsman Cancer Institute, Salt Lake City
Collaborators (1)
Oryzon Genomics S.A.
INDUSTRY
Fox Chase Cancer Center
OTHER